BioLineRx Ltd.

BLRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.50

+$0.02 (+0.81%)

Sep 22, 2026, 2:26 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.81%

(1D)

Rating

Updated: Aug 28, 2026

30.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $10.88M

1D Range

2.42 2.60

52W Range

2.15 4.56

Valuation (TTM)

PE -1.38

PB 0.78

EV/EBITDA -0.68

Valuation (NTM)

Forward PE N/A

Forward PEG 0.07

Price Target N/A

Cash Flow

FCF Yield -101.0%

SBC Adj. FCF Yield -102.7%

SBC Impact -1.6%

Margins

Gross Margin 70.0%

Operating Margin -876.3%

FCF Margin -779.6%

Growth (CAGR)

Revenue 3Y | 5Y -65.8% | 28.1%

Dil EPS 3Y | 5Y 106.9% | 41.6%

FCF 3Y | 5Y 46.9% | 14.7%

Returns

ROA -24.2%

ROE -47.2%

ROIC -50.1%

Financial Health

Net Cash

$6.1M

Current Ratio 1.20

Interest Coverage -11.65

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational pr...

Sector Healthcare

Industry Biotechnology

Employees 22

IPO Date Jul 26, 2011

Website www.biolinerx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 31, 2026

EPS

-$0.77

Miss -413.33%

YoY: +23.00%

REV

$294K

Miss -41.20%

YoY: -3.29%

Next Earnings

Nov 23, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞